Roche

Evotec partners with Roche in $820 million Alzheimer’s deal

Tuesday, September 6, 2011 01:10 PM

Evotec has signed a new agreement with partner Roche to develop a compound with potential in Alzheimer's disease, replacing an antidepressant program which was dropped in May, according to PharmaTimes.

More... »

Roche CEO says diagnostics will maintain its lead in targeted drugs

Thursday, September 1, 2011 02:15 PM

Roche expects a new generation of drugs targeted at specific groups of patients to make up half its portfolio in 10 years, a shift that is pushing the boundaries of modern medicine, according to Reuters.

More... »

DVS Sciences raises $14 million, largest round in Canada life sciences, to expand CyTOF sales

Monday, August 29, 2011 08:00 AM

DVS Sciences, which invented and manufactures an instrument enabling biomarker analysis for scientific research, clinical trials and personalized medicine, has raised $14.6 million in series A financing. This is the largest venture-backed series A equity raised in Canada’s life sciences and medical technology fields in recent years, and is almost twice the average series A funding in the U.S., the company said.

More... »

American Cancer Society enrolls thousands in prevention study

Wednesday, August 24, 2011 11:33 AM

For the past two years, the American Cancer Society has been enrolling people across the country in its latest research project, cancer prevention study-3, according to a report in the Indianapolis Star. In the first week of October, eight of Indianapolis’ major employers will contribute, signing up people at their work sites.

More... »

Roche buys Canadian R&D facility for $190 million

Wednesday, August 17, 2011 12:57 PM

Roche has said it intends to establish a "major global pharmaceutical development site" in Ontario, Canada, creating around 200 skilled jobs, according to PharmaTimes.

More... »

DecisionView to launch enrollment-centric metrics

Monday, August 15, 2011 08:00 AM

Clinical trial enrollment-focused software maker DecisionView is launching what it says will be the first benchmarking effort to focus tightly on enrollment metrics.

More... »

Array signs $685 million agreement with Genentech

Tuesday, August 9, 2011 12:08 PM

Array BioPharma has signed an oncology agreement with Genentech, a member of the Roche Group, for the development of each company's small-molecule checkpoint kinase 1 (ChK-1) program. The programs include Genentech's compound GDC-0425 (RG7602), currently in phase I, and Array's compound ARRY-575, which is being prepared for an investigational new drug application to initiate a phase I trial in cancer patients.

More... »

Roche seeks compromise with FDA over Avastin

Monday, August 8, 2011 01:41 PM

In a bid to salvage the breast cancer indication for Avastin, Roche’s Genentech unit has pitched to the FDA what it is calling a “middle-ground proposal” that would allow the drug to retain its indication and only for use with paclitaxel. The deal includes revised labeling in which Avastin would be recommended only for patients displaying “aggressive disease” and who have the fewest treatment options. Roche also suggests a Risk Evaluation and Mitigation Strategy, or REMS, as well as a Medication Guide, according to Pharmalot.

More... »

Roche names president of Ventana Medical Systems

Monday, August 1, 2011 12:09 PM

Ventana Medical Systems, a member of the Roche Group, has named Mara Aspinall president. Aspinall will begin her new role at Ventana in September 2011.

More... »

Roche to acquire mtm laboratories

Tuesday, July 19, 2011 01:05 PM

Ventana Medical Systems, a member of the Roche Group, has said Roche will acquire 100% of mtm laboratories, a privately-held company based in Heidelberg, Germany. mtm is a global developer in vitro diagnostics with a focus on early detection and diagnosis of cervical cancer, the largest early detection market in oncology. mtm will become part of Roche's Tissue Diagnostics (Ventana Medical Systems) business unit. Roche will pay mtm shareholders an upfront payment of approximately $180 million as well as up to approximately $85 million upon reaching performance-related milestones.

More... »